BR112022008908A2 - Sistemas de permanência gástrica para administração de agentes ativos - Google Patents

Sistemas de permanência gástrica para administração de agentes ativos

Info

Publication number
BR112022008908A2
BR112022008908A2 BR112022008908A BR112022008908A BR112022008908A2 BR 112022008908 A2 BR112022008908 A2 BR 112022008908A2 BR 112022008908 A BR112022008908 A BR 112022008908A BR 112022008908 A BR112022008908 A BR 112022008908A BR 112022008908 A2 BR112022008908 A2 BR 112022008908A2
Authority
BR
Brazil
Prior art keywords
gastric
systems
disclosed
permanence
active agents
Prior art date
Application number
BR112022008908A
Other languages
English (en)
Inventor
KANASTY Rosemary
GRANT Tyler
Altreuter David
Weight Alisha
Moorthy Saumya
Tai Tammy
Jaramillo Montezco Juan
Schwarz Marlene
Hoon Yang Jung
TRAN Jeanne
Duan Michelle
Jing Jie
C Dufour David
Robert Waldemar Ryde Erik
Bhise Nupura
Holar Sonia
De La Torre Nicholas
Simses Craig
Beguin Estelle
Lai Erica
Peeke Erick
Original Assignee
Lyndra Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lyndra Therapeutics Inc filed Critical Lyndra Therapeutics Inc
Publication of BR112022008908A2 publication Critical patent/BR112022008908A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SISTEMAS DE PERMANÊNCIA GÁSTRICA PARA ADMINISTRAÇÃO DE AGENTES ATIVOS. Sistemas de residência gástrica para administração de agentes, tais como drogas, são divulgados. São divulgadas características que aumentam a retenção gástrica durante o tempo de residência desejado e que permitem um controle mais preciso sobre o tempo de residência, incluindo filamentos circunferenciais que conectam os braços de um sistema de residência gástrico estrelado; braços flexíveis para sistema de residência gástrica; matrizes de desintegração entérica e dependentes do tempo melhoradas (ligantes); e revestimentos poliméricos moduladores da taxa de liberação que são resistentes à mudança nas propriedades da taxa de liberação durante a montagem assistida por calor ou ciclo térmico. Combinações dessas características também são divulgadas.
BR112022008908A 2019-11-08 2020-11-06 Sistemas de permanência gástrica para administração de agentes ativos BR112022008908A2 (pt)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201962933226P 2019-11-08 2019-11-08
US201962933211P 2019-11-08 2019-11-08
US201962933210P 2019-11-08 2019-11-08
US201962933313P 2019-11-08 2019-11-08
US201962933348P 2019-11-08 2019-11-08
US202062992075P 2020-03-19 2020-03-19
US202063052905P 2020-07-16 2020-07-16
PCT/US2020/059541 WO2021092491A1 (en) 2019-11-08 2020-11-06 Gastric residence systems for administration of active agents

Publications (1)

Publication Number Publication Date
BR112022008908A2 true BR112022008908A2 (pt) 2022-10-11

Family

ID=75849597

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022008908A BR112022008908A2 (pt) 2019-11-08 2020-11-06 Sistemas de permanência gástrica para administração de agentes ativos

Country Status (10)

Country Link
US (1) US20220387311A1 (pt)
EP (1) EP4054545A4 (pt)
JP (1) JP2022553862A (pt)
CN (1) CN115003335A (pt)
AU (1) AU2020378438A1 (pt)
BR (1) BR112022008908A2 (pt)
CA (1) CA3160665A1 (pt)
IL (1) IL292849A (pt)
MX (1) MX2022005494A (pt)
WO (1) WO2021092491A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022159529A1 (en) * 2021-01-19 2022-07-28 Lyndra Therapeutics, Inc. Gastric residence systems for administration of risperidone

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101728868B1 (ko) * 2006-01-18 2017-05-02 포시 파마슈티컬스 컴퍼니 리미티드 안정성이 강화된 약학 조성물
EP2600902A4 (en) * 2010-08-06 2015-01-07 Endoshape Inc X-RAY DENSITY RESIN POLYMERS FOR MEDICAL DEVICES
CN108472249A (zh) * 2015-10-23 2018-08-31 林德拉有限公司 用于治疗剂缓释的胃驻留系统及其使用方法
CA3025650A1 (en) * 2016-05-27 2017-11-30 Lyndra, Inc. Materials architecture for gastric residence systems
CN110022861A (zh) * 2016-09-30 2019-07-16 林德拉有限公司 用于金刚烷类药物缓释的胃驻留系统
CN110996906A (zh) * 2017-06-09 2020-04-10 林德拉有限公司 具有调节释放速度的膜的胃驻留系统
US11793751B2 (en) * 2017-09-20 2023-10-24 Lyndra Therapeutics, Inc. Encapsulation of gastric residence systems

Also Published As

Publication number Publication date
MX2022005494A (es) 2022-08-11
US20220387311A1 (en) 2022-12-08
EP4054545A1 (en) 2022-09-14
CN115003335A (zh) 2022-09-02
EP4054545A4 (en) 2024-02-14
CA3160665A1 (en) 2021-05-14
IL292849A (en) 2022-07-01
JP2022553862A (ja) 2022-12-26
AU2020378438A1 (en) 2022-06-02
WO2021092491A1 (en) 2021-05-14

Similar Documents

Publication Publication Date Title
BR112019023985A2 (pt) sistema de autocorreção e componentes e métodos relacionados
BR112022008908A2 (pt) Sistemas de permanência gástrica para administração de agentes ativos
BR112018003882A2 (pt) material auxiliar para proporcionar eluição de fármaco de vasos
BR112021022517A2 (pt) Dispositivos de selagem de válvulas cardíacas, dispositivos de liberação para eles, e dispositivos de recuperação
BR112018069483A2 (pt) pró-fármacos de medicamentos citotóxicos contendo grupos enzimaticamente cliváveis.
BR112022002683A2 (pt) Agonistas não peptídicos do receptor de somatostatina tipo 5 e seus usos
BR0312445A (pt) Sistemas multiunitários para disponibilização de fármaco de liberação modificada
BR112012009185A2 (pt) realimentação e controle de dose de sistemas de descontaminação distribuída
BR112016024764A2 (pt) cateter dotado de porta ou encaixe luer fêmea com septo antimicrobiano
BR112019001921A2 (pt) moduladores do receptor nmda de espiro-lactama e seus usos
BR112019001768A2 (pt) moduladores do receptor de spiro-lactamas nmda e usos dos mesmos
BR112017014390A2 (pt) cateter intravenoso de segurança com retenção à base de fricção e característica de deslocamento
BR112017016342A2 (pt) entrega de partículas de agentes ativos hidrofóbicos
BR112015002755A8 (pt) Derivado de ácido hialurônico, método de preparação de derivado de ácido hialurônico e uso de derivados
BR112017022659A2 (pt) dispositivo de administração de medicamento com propulsor de gás
BR112019001923A2 (pt) moduladores de nmda de espiro-lactama e métodos de sua utilização
CO2021006308A2 (es) Proteínas f de prefusión del vrs estabilizadas
HRP20201683T1 (hr) Imunogeni pripravak namijenjen upotrebi u terapiji
BR112017016245A2 (pt) cateter, sistema para administração de temperatura alvo e método para administração de temperatura alvo corporal
AU2019301069A8 (en) Mixing/administration system for vaccines and medicaments
BR112018072883A8 (pt) Sistema de implante subdérmico do agente antiviral 4'-etinil-2-fluoro-2'-desoxiadenosina com polímero eva e seu uso
BR112019023260A2 (pt) Fatores de crescimento de fibroblastos recombinantes modificados e seus usos terapêuticos
Domínguez-Andrés et al. Designing the next generation of vaccines: relevance for future pandemics
CL2021002107A1 (es) Triamtereno o nolatrexed para uso en el tratamiento de fenilcetonuria.
BR112018003843A2 (pt) compostos auxiliares cirúrgicos tendo medicamentos liberados de maneira controlável dos mesmos

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B04C Request for examination: application reinstated [chapter 4.3 patent gazette]